The DOI matches its Crossref record; 168 of the 169 references it cites were found in a registry or an index.
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Open accessAbstract
Nonalcoholic fatty liver disease is the most prevalent liver disease worldwide, affecting 20%-25% of the adult population. In 25% of patients, nonalcoholic fatty liver disease progresses to nonalcoholic steatohepatitis (NASH), which increases the risk for the development of cirrhosis, liver failure, and hepatocellular carcinoma. In patients with NASH, liver fibrosis is the main determinant of mortality. Here, we review how interactions between different liver cells culminate in fibrosis development in NASH, focusing on triggers and consequences of hepatocyte-macrophage-hepatic stellate cell (HSC) crosstalk. We discuss pathways through which stressed and dead hepatocytes instigate the profibrogenic crosstalk with HSC and macrophages, including the reactivation of developmental pathways such as TAZ, Notch, and hedgehog; how clearance of dead cells in NASH via efferocytosis may affect inflammation and fibrogenesis; and insights into HSC and macrophage heterogeneity revealed by single-cell RNA sequencing. Finally, we summarize options to therapeutically interrupt this profibrogenic hepatocyte-macrophage-HSC network in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [9]
In the citing paper
“The perisinusoidal fibrosis in early human NASH is thought to be produced by activated HSCs/myofibroblasts.114”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [114]
In the citing paper
“The disease-driving pathways of NASH converge in fibrosis (Fig. 3), an aberrant wound-healing process resulting not only in scarring (extracellular matrix deposition), but also in the loss of functional hepatocytes and chronic inflammation.104”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [104]
In the citing paper
“The disease-driving pathways of NASH converge in fibrosis (Fig. 3), an aberrant wound-healing process resulting not only in scarring (extracellular matrix deposition), but also in the loss of functional hepatocytes and chronic inflammation.104”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [104]
In the citing paper
“Furthermore, monocytes and macrophages are capable of remarkable functional plasticity, displaying diverse phenotypes during wound healing dependent on multiple cues including the environmental niche61,62 and the temporal stage of tissue injury and repair63–66.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
In the citing paper
“demonstrated that the absence of Lyve1hiMHCIIlo IMs exacerbates experimental lung fibrosis, thereby showing that two independent populations of IMs coexist across tissues with conserved niche-dependent functional programs61.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
In the citing paper
“Two independent IM subpopulations that are conserved across lung, fat, heart, and dermis were identified: (Lyve1loMHCIIhiCX3CR1hi (Lyve1loMHCIIhi) and Lyve1hiMHCIIloCX3CR1lo (Lyve1hiMHCIIlo) monocyte-derived IMs.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
In the citing paper
“Several recent studies have identified subpopulations of monocytes and macrophages which have the capacity to regulate fibrosis and tissue remodelling18,61,68–71.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors
Gomez Perdiguero, E., Klapproth, K., Schulz, C., Busch, K., Azzoni, E., Crozet, L., Garner, H., Trouillet, C., de Bruijn, M. F., Geissmann, F., et al. (2015) · Nature · doi:10.1038/nature13989 · Cited by 2,339
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citation
Research works printed but not linked: 2
- Mooring, 2019, Hepatocyte stress increases expression of YAP and TAZ in hepatocytes to promote parenchymal inflammation and fibrosis, Hepatology
- Song, 2019, YAP in Kupffer cells enhances the production of pro-inflammatory cytokines and promotes the development of non-alcoholic steatohepatitis, Hepatology
Cited by
Sorted by citations
Items 601–679 of 679
Bando, T., Sato, H., Uno, S., Morita, H., Zreka, L., Ma, S., Khan, M., Akuzawa, D., Masuo, Y., Matsuyama, J., et al. (2025) · International Immunology · doi:10.1093/intimm/dxaf055
Du, X., Wang, M., Wang, Z., Xue, Z., Gao, Y., Ma, Y., Wang, Z., Liu, S., Ji, M., Yang, Y., et al. (2025) · Journal of Environmental Sciences · doi:10.1016/j.jes.2025.09.032
Shooting for the stars: caspase-8–meteorin in MASH and fibrosis
Gallage, S., Bieler, T., & Heikenwälder, M. F. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01361-3
HSD17B13 Couples Hepatocyte Lipid Metabolism to Stellate Cell Activation via TGFb-1 SignalingPreprint
Raymond, N., Lifshitz, L. M., Min, K., Lewis, C. A., Isaac, G., Yenilmez, B., & Czech, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.682191 · Cited by 1
Li, Z., Guo, C., Ye, X., Xu, Q., Weng, L., Gao, Y., Ge, R., & Lin, X. (2025) · ACS Omega · doi:10.1021/acsomega.5c07073
Yang, R., Feng, L., Gong, Z., Yang, H., Du, H., Chen, J., Qin, M., Chen, N., Huang, H., Wang, P., et al. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05099-z
Zhuang, Z., Zhuge, F., Liu, Y., Song, Y., Luo, Y., Liu, J., Yang, W., Kong, J., Zhang, H., Yang, J., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04275-2
Motta, B. M., Rosati, A., Festa, M., Basile, A. M., Sarcina, T., Turco, M. C., & Persico, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311286
Yang, X., Xie, D., Du, Y., Zhang, D., Chen, H., & Yuan, Y. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04504-8
Emerging role of FUS in TGFB1 and COL1A1 transcription dependent on GADD45B to induce NASH-fibrosis
Wu, C., Ding, Q., Zeng, Z., Yang, L., Song, X., Zhang, M., Lu, P., Zhu, R., Du, Z., Luo, Y., et al. (2025) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf049
Role of connexin32 in zinc oxide nanoparticles induced hepatotoxicity
Wei, E., Wu, L., Xia, G., Zhong, Y., Li, L.-G., Chen, H., & Tang, N. (2025) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2604731
Hany, N. M., Eissa, S., Basyouni, M., Hasanin, A. H., Aboul-Ela, Y. M., Magd, N. M. A. E., Montasser, I. F., Ali, M. A., Skipp, P. J. S., & Matboli, M. (2022) · Figshare · doi:10.6084/m9.figshare.20408668
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921187
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921193
He, W., Huang, Y., Shi, X., Wang, Q., Wu, M., Li, H., Liu, Q., Zhang, X., Huang, C., & Li, X. (2023) · Figshare · doi:10.6084/m9.figshare.23639929
Liu, Y., Chen, H., Yan, X., Zhang, J., Deng, Z., Huang, M., Gu, J., & Zhang, J. (2024) · Figshare · doi:10.6084/m9.figshare.25116176
Liu, Y., Chen, H., Yan, X., Zhang, J., Deng, Z., Huang, M., Gu, J., & Zhang, J. (2024) · Figshare · doi:10.6084/m9.figshare.25115986
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lu, Q., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24580347
He, W., Huang, Y., Shi, X., Wang, Q., Wu, M., Li, H., Liu, Q., Zhang, X., Huang, C., & Li, X. (2023) · Figshare · doi:10.6084/m9.figshare.23639926
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921199
Ueda, R., & Shoji, H. (2025) · Forma · doi:10.55653/forma.2025.001.004
Neuropilin-1 Acts as a co-receptor of IL-13 to reprogram macrophages in liver fibrosis.
Liu, C., Wang, Y., Yang, Y.-N., Tian, M., Liu, T.-T., Zhao, S.-B., Wang, L., Gao, L.-F., Feng, Y.-M., Qi, J.-N., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108112
Zeng, G., Li, G., Lin, X., Shoude, Y. A. N. G., & Zeng, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1571261
Zhang, X., Cheng, Y., Yu, R., Hu, X., & Huang, Y. (2026) · PLoS ONE · doi:10.1371/journal.pone.0332881
Patel, V., Navale, A. M., & Singh, P. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02306-x
Chen, H., Yang, M., Tu, X., Li, J., Li, C., & Xia, J. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.03.001
Fibrose hépatique : physiopathologie, diagnostic, pronostic
Gilgenkrantz, H., Bédossa, P., & Pol, S. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)43565-7
Zhang, R., Yang, Y., Xiao, F., He, Y., Chai, Y., Qiu, J., Zhu, Q., Sun, W., Chen, M., & Xu, Z. (2026) · Inflammation Research · doi:10.1007/s00011-026-02220-x
Palmitoleic acid promoted by BMPR2 signaling primes CD169 macrophages and alleviates liver fibrosis
Ma, H., Zhong, J., Peng, Q., Dai, M., Wang, L., Wang, J., Huang, D., Liu, Y., Tang, Y., Xu, W., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09972-6
La nécroptose : une nouvelle cible thérapeutique dans la stéatohépatite non-alcoolique
Majdi, A. (2020) · theses.fr (ABES) · doi:10.70675/94f28bbaz6c2dz4b48zb1aaze6b48ca72708
Rôle de REG3A dans la maladie métabolique du foie d'origine nutritionnelle
Nguyen, T.-S. (2024) · theses.fr (ABES) · doi:10.70675/2c0ffdcfz96ccz43b0z8e03zb358f83e528d
Rôle de FAT10 dans la sénescence des hépatocytes et le développement de la NASH
Bernard, L. (2023) · theses.fr (ABES) · doi:10.70675/793b0b93z9794z42d4zb8dfz5f3d68268a9b
Zhang, L., Wang, W., 郑凤婷, Weng, J., Lu, Y., Li, Q., Li, T., Li, W., & Wang, L. (2026) · Metabolites · doi:10.3390/metabo16040285
Zhang, C., Zhang, Z., Qi, Q., Li, L., Deng, J., Zheng, J., Jiang, Y., Han, Q., Wu, S., & Li, K. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s570754
Lee, Y., Kim, I. S., Kim, J. W., Kim, M. K., Chae, Y. G., Choi, C. S., Kwon, O. S., Kim, Y. I., Kim, J. H., Chung, D. H., et al. (2026) · Free Radical Research · doi:10.1080/10715762.2026.2668102
Elsaid, M. I., Kweon, Y., Li, N., Fernández, S., Paskett, E. D., Mumtaz, K., & Rustgi, V. K. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.100992
Shi, M., Zhang, G., Zhou, H., Li, Y., Hou, Y., Yang, X., Liu, L., & Tong, G. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1804716
Reduction in Hepatic Phosphatidylcholine Biosynthesis Promotes MASH Through Copper DeficiencyPreprint
Welles, J. E., Garifallou, J. P., Gonzalez, M. V., Santoleri, D., Choudhury, F. K., DeNicola, G. M., Martin, R. W., Jiang, C., Kim, J., Li, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.723926
Molecular Mechanism of POSTN Mediating M2 Polarization of Kupffer Cells to Promote Hepatic Fibrosis
Wang, M., Yuan, S., Mijit, A., Zhang, W., Wu, Y., & Cheng, L.-F. (2026) · Pharmaceuticals · doi:10.3390/ph19050752
Ding, S., Liu, Y., Liu, Z., Chu, F., Lu, B., & Xu, L. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s569506
Sun, X., Jiang, H.-L., Ma, Y.-T., Xiong, T.-Q., Leng, X.-Y., Zhao, Y.-F., Shen, X., Zhang, C., & Tang, Y.-J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08219-6
Wan, K., Zhou, Q., Feng, R., Fan, C., Shi, W., Xu, W., Jiang, H., & Zhou, Q. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02437-9
Wang, Q., Chen, H., Ran, Q., Hu, F., Fu, Q., & Ma, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115123
Decoding circRNA–miRNA crosstalk in the pathogenesis of hepatic fibrosis: A comprehensive review
Kumar, P., Rawat, P., Helal, M., Sharma, A., Magisetty, J., & Kondreddy, V. K. R. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153022
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
The PERK–GADD45A axis is a key driver of hepatic stellate cell activation
Barupala, N. P., Misra, J., Bibian, E., Baxter, R., Singh, V., Xique, N., Goins, E. D., Jackson, A., Ebert, S. M., Adams, C. M., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000980
Khalil, I., Sarker, P., Hossain, M. S., Chowdhury, A., Khalid, A. A., Saha, A., Chowdhury, J., Akter, M. M., Promi, S. A., Sayed, M. A., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.004
Wei, W., Ma, Q., Huang, L., & Lin, W. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345887
Effect of Short-Chain Fatty Acids In Vivo on the Treatment of CCL4-Induced Hepatic Fibrosis
Rodrigues, K. F., Tonial, G. V., Bastos, M. S., Pavanato, G. M., Luft, C., Garcia, M. C. R., Maito, F. L. D. M., Campos, M. M., & de Oliveira, J. R. (2026) · Biomedicines · doi:10.3390/biomedicines14071477
Khalil, I., Sarker, P., Nur, N., Hossain, M. S., Khalid, A. A., Al-Badri, S. G., Akter, M. M., Das, M., & Rahman, M. T. (2026) · Hepatology International · doi:10.1007/s12072-026-11122-3
Gerold, A., Walter, F.-S., Waller, J., & Ferger, B. (2026) · BMC Oral Health · doi:10.1186/s12903-026-09067-y
Mangla, K. K., Gbadamosi, S. O., Semeniuta, D., Bandaria, J. N., Zabinski, J. W., Curhan, G. C., & Boussios, C. (2026) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848261462398
Molecular PET imaging of integrin αvβ6 reveals biliary and fibrotic changes in preclinical MASH
Wang, X., Wang, M., Han, P., Song, H., Zhao, X., Chen, N., Hu, C., Liu, X. F., Li, X., Fu, X., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00965-5
Lv, T.-S., Dai, H., Zhang, S., Chang, E., Ni, M., Ge, J., Cao, Y., Cheng, Z., He, Y., Huai, J., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01716-9
Naeem, M. Y., & Ijaz, T. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02236-3
Wen, Q., Yin, X.-M., Liu, C.-Y., Li, C.-F., & Yuan, X.-X. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70347
Xia, Z., Liu, H., He, Z., Zhou, J., Zhang, S., Xi, Y., Zhou, C., Huang, X., Ruan, C., Mao, K., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158620
Tacke, F., Detjen, K. M., Heisig, J., & Hampe, J. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2890-7253
Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine
Lonardo, A., & Weiskirchen, R. (2026) · Metabolites · doi:10.3390/metabo16080529
Kim, G.-H., Rho, H., Lee, C. H., Hong, Y.-J., Park, Y. R., Yu, H. C., Song, M.-Y., Jo, H. J., Kang, E. J., Han, R., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02796-0
Wang, K., Shen, H., Shi, J., & Fu, J. (2026) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-026-00766-9 · Cited by 1
Huang, Y., Lu, J., & Wang, H. (2026) · medRxiv · doi:10.64898/2026.08.02.26359499
Liu, X., Li, Y., Guan, J., Fan, L., Li, S., Hassan, W., Ahmed, H., Cheng, L., & Yingqi, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1810588
Ren, Y., Hu, D., Li, L., Wang, L., & Meng, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911290
Ling, H., Qiu, P., & Hu, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177920
Suganami, T., Tanaka, M., & Itoh, M. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109123
Mahadule, D., Gangwar, A., Purohit, K. J., Sarmah, N. R., Yadav, N., Singh, H., Shelke, A., Navale, A. M., & Wakchaure, R. S. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00719-7
Foglia, B., Nurcis, J., Signorini, M., Novo, E., Bocca, C., Cannito, S., & Parola, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188213
Abnormal lipid metabolism in metabolic dysfunction-associated steatohepatitis (MASH)
Lee, W., Choi, Y., Park, H., Chae, S., & Lee, B. (2026) · Toxicological Research · doi:10.1007/s43188-026-00387-3
Wang, B., Dong, X., Li, J., Feng, X., Chen, Y., Liu, N., Fu, P., Wang, J., & Li, X. (2026) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2026.105179
MASH and Chronic Viral Hepatitis: Pathophysiology, Diagnosis, and Management
Olaiya, V. O., Ejeheri, F. O., Osinuga, T. S., Ajayi, A. A., Okeke, C., Ajayi, A., Nwoye, V. T., Makinde-Ojo, S., Eze, M. C., Eze, A., et al. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02729-6
Glutamine metabolism in health and disease
Zhao, J., Lin, Y., Gao, R., Gao, H., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02981-1
da Silva, S. R. B., Cristina‐Rodrigues, F., Chaves, M. M., Cruz, I. P., da Cruz, L. D. O., de Araujo, M. F. C., Cavalcanti, S. N. V., Atella, G. C., Takiya, C. M., Savio, L. E. B., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1909005
Immunophenotypic subtypes of MAFLD distinct activity, comparable fibrosis
Ding, Y., 陈明霞, Kong, F., liu, T., Zhu, L., Zhang, W., Yu, H., & Xia, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-60628-1
Wang, X., Mei, J., Li, R., Zhang, Y., Zhao, G., Hu, Y., Yan, G., Sun, H., & Lv, H. (2026) · Human Reproduction · doi:10.1093/humrep/deag160
Antifibrotic therapy in MASLD: fibrosis reversal and HCC prevention
Roeb, E., & Weiskirchen, R. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.90
Li, R., Huang, X., Li, S., & Zhang, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1916728
Jung, E. J., & Wang, X. (2026) · iNew Medicine · doi:10.1002/inm3.70097
Metadata
- Authors
- Schwabe, R. F., Tabas, I., & Pajvani, U. B.
- Affiliations
- Columbia University Irving Medical Center (US)
- Columbia University (US)
- Corresponding author
- Schwabe, Robert F.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 158
- Issue
- 7
- Pages
- 1913-1928
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC7682538
- OpenAlex
- W3005214954
- Cited by
- 671
- References
- 169
- Citations by year
- 2026: 82 · 2025: 121 · 2024: 138 · 2023: 131 · 2022: 117 · 2021: 53 · 2020: 27
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- nonalcoholic steatohepatitis, liver fibrosis, hepatic stellate cells, macrophages, hepatocyte death, efferocytosis, TAZ, Notch signaling, Hedgehog signaling, single-cell RNA sequencing, antifibrotic therapy, non-alcoholic fatty liver disease
- MeSH terms
- Animals, Cell Communication, Extracellular Matrix, Humans, Liver, Liver Cirrhosis, Macrophages, Signal Transduction, Cell Death, Hepatocytes, Hepatic Stellate Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
